Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-18

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma

NCT04915417

Resectable Pancreatic Adenocarcinoma Borderline Resectable Pancreatic Adenocarcinoma

UNKNOWN NA

SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist

NCT03950102

Hepatocellular Carcinoma

UNKNOWN NA

Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation

NCT00178243

Liver Neoplasms Neoplasm Metastasis

COMPLETED PHASE1/PHASE2

Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer

NCT01346410

Pancreatic Cancer

COMPLETED NA

Stereotactic Radiosurgery for Patients With Hepatic Metastases.

NCT00547677

Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

The primary objectives of this prospective pilot study is to:

1. determine the feasibility and reproducibility of 3D contrast enhanced ultrasound imaging in liver cancer patients undergoing Stereotactic Ablative Radiotherapy and
2. evaluate whether there are treatment induced early changes in imaging metrics derived from 3D contrast enhanced ultrasound. This study will provide valuable insight as to the potential of baseline and/or early post-treatment 3D ultrasound perfusion characteristics (measurements of blood-flow) of primary and metastatic liver tumors to predict tumor response to Stereotactic Ablative Radiotherapy. The investigators' underlying goal is to assess whether early perfusion changes at 1-7 days after SABR initiation can be used as a non-invasive early biomarker for treatment response assessment.

Secondary Objectives:

Evaluate the feasibility of contrast-enhanced ultrasound-to-CT fusion by assisting three-dimensional (3D) perfusion ultrasound (US) imaging with optical and electromagnetic tracking of the ultrasound probe on patients with liver cancer that will undergo CT for treatment planning and/or response evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer Liver Tumor Hepatocellular Carcinoma Liver Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3D Perfusion Ultrasound

undergo 3D ultrasound perfusion imaging with perflutren

Group Type EXPERIMENTAL

perflutren lipid microspheres

Intervention Type DRUG

3D ultrasound

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

perflutren lipid microspheres

Intervention Type DRUG

3D ultrasound

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Definity

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand and willingness to sign the written informed consent document
* Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative Radiotherapy (SABR)
* Patient is at least 18 years of age. No gender/race-ethnic restrictions.
* Performance status (ECOG) between 0-3
* History and Physical done within 4 weeks of enrollment.

Exclusion Criteria

* Patient has previously been enrolled in and completed this study.
* Known right to left cardiac shunt, bidirectional or transient.
* Patient has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.
* History of hypersensitivity to the contrast agent perflutren
* History of pulmonary hypertension
* Patients who are pregnant or are trying to become pregnant

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No